How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond?
We conducted a blind and independent “voice of the customer” industry survey in late Q4 2020 and into Q1 2021 with the opt-in online readership of Contract Pharma to ascertain what impact COVID-19 had – and was continuing to have – on outsourcing decisions for those who sought CRO, CDMO, or both CRO and CDMO services in the global pharmaceutical industry.
The insights provided by survey respondents reveal what happened within the outsourcing industry in 2020, where it’s going in 2021, and the role COVID-19 played in dramatically shifting attitudes, preferences and actions within the global pharmaceutical supply chain.
Here is a sample of some of the questions the report’s respondents answer in often unexpected ways:
Download the report to see these answers and much more.
Offered Free by: August Bioservices
See All Resources from: August Bioservices
This download should complete shortly. If the resource doesn't automatically download, please, click here.